- |||||||||| Phase classification: PanACEA - STEP2C -01 (clinicaltrials.gov) - Dec 1, 2023
P2, N=360, Recruiting,
Phase classification: P2b --> P2 Phase classification: P2b --> P2
- |||||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development, Sirturo (bedaquiline) / J&J, Pharmstandard, Sutezolid (PNU-100480) / Sequella
Enrollment open, Trial initiation date: panTB-HM: A Pan-TB Regimen Targeting Host and Microbe (clinicaltrials.gov) - Aug 16, 2023
P2/3, N=352, Recruiting,
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> Jul 2023
- |||||||||| Enrollment open: PanACEA - STEP2C -01 (clinicaltrials.gov) - Apr 18, 2023
P2b, N=360, Recruiting,
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| New P2b trial: PanACEA - STEP2C -01 (clinicaltrials.gov) - Apr 11, 2023
P2b, N=360, Not yet recruiting,
- |||||||||| Baxdela (delafloxacin) / Menarini, Melinta Therap, Sutezolid (PNU-100480) / Sequella
Journal: Assessment of Lipophilicity Parameters of Antimicrobial and Immunosuppressive Compounds. (Pubmed Central) - Mar 30, 2023
The presented results demonstrate that RP-TLC method may be a good tool in determining the lipophilic properties of studied substances. Obtained lipophilic parameters of the compounds can be valuable in the design of their new derivatives as efficient antimicrobial and immunosuppressive agents.
- |||||||||| rifampicin / Generic mfg., Sutezolid (PNU-100480) / Sequella
Journal: Adaptation to the intracellular environment of primary human macrophages influences drug susceptibility of Mycobacterium tuberculosis. (Pubmed Central) - Mar 14, 2023
We observed that hypoxia induced greater lipid body formation and no additional shifts in drug tolerance, suggesting that the adaptation of intracellular Mtb to baseline host cell conditions under normoxia dominates changes to intracellular drug susceptibility. Using unbound plasma concentrations in patients as surrogates for free drug concentrations in lung interstitial fluid, we estimate that intramacrophage Mtb in granulomas are exposed to bacteriostatic concentrations of most study drugs.
- |||||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development, Sirturo (bedaquiline) / J&J, Pharmstandard, Sutezolid (PNU-100480) / Sequella
New P2/3 trial: panTB-HM: A Pan-TB Regimen Targeting Host and Microbe (clinicaltrials.gov) - Jan 17, 2023
P2/3, N=352, Not yet recruiting,
- |||||||||| rifampicin / Generic mfg.
Review, Journal: Annual progress of chemotherapy of multidrug/rifampicin-resistant tuberculosis in 2022 (Pubmed Central) - Jan 10, 2023
Meanwhile, different new chemotherapy regimens centered on new drugs have been explored in-depth by international scholars. In this article, we reviewed the progress of chemotherapy of multidrug/rifampicin-resistant tuberculosis from October 2021 to September.
- |||||||||| SQ-109 / Sequella
Review, Journal: MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature. (Pubmed Central) - Nov 16, 2022
SQ109 has demonstrated activity against drug-sensitive (DS) and drug-resistant (DR) Mycobacterium tuberculosis (Mtb) and a synergistic effect with isoniazid (INH), rifampicin (RIF), clofazimine (CFZ), and bedaquiline (BNQ)...The combinations of SQ109 with other anti-TB drugs (chloroquine, hydroxychloroquine, and sutezolid) have also been claimed in the patent literature...Developing MmpL3 inhibitors is a promising approach to fighting the challenges associated with DS-TB and DR-TB. The authors foresee MmpL3 inhibitors such as SQ109 as future drugs for TB treatment.
- |||||||||| Trial primary completion date, Combination therapy: SUDOCU: PanACEA Sutezolid Dose-finding and Combination Evaluation (clinicaltrials.gov) - Aug 11, 2022
P2b, N=75, Active, not recruiting,
Such convenient extraction methods and the use of stable isotope-labelled drugs as internal standards provide an accurate and precise quantification of plasma concentrations of all major clinically-used antiTB drugs regimens and is optimally suited for clinically efficient TDM against tuberculosis. Trial primary completion date: Apr 2022 --> Oct 2022
- |||||||||| Journal: Discovery and Development of Antibacterial Agents: Fortuitous and Designed. (Pubmed Central) - May 26, 2022
This article aims to review the investigational and recently approved antibacterials with a focus on their structure, mechanisms of action/resistance, and spectrum of activity. Delving deep, their success or otherwise in various phases of clinical trials is also discussed while attributing the same to various causal factors.
- |||||||||| Sutezolid (PNU-100480) / Sequella
PK/PD data, Journal: Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects. (Pubmed Central) - Apr 22, 2022
Maximum concentration (C) of sutezolid, PNU-101603, and PNU-101244 increased in a less-than-proportional manner with an increase in sutezolid dose between 300 mg and 1,800 mg. Total exposure (AUC [area under the concentration-time curve from time zero to the time of the last quantifiable concentration] and AUC [area under the plasma concentration time curve from time zero extrapolated to infinity]) of sutezolid, PNU-101603, and PNU-101244 increased proportionally with an increase in sutezolid dose.
- |||||||||| Enrollment closed, Combination therapy: SUDOCU: PanACEA Sutezolid Dose-finding and Combination Evaluation (clinicaltrials.gov) - Feb 21, 2022
P2b, N=75, Active, not recruiting,
Total exposure (AUC [area under the concentration-time curve from time zero to the time of the last quantifiable concentration] and AUC [area under the plasma concentration time curve from time zero extrapolated to infinity]) of sutezolid, PNU-101603, and PNU-101244 increased proportionally with an increase in sutezolid dose. Recruiting --> Active, not recruiting
- |||||||||| rifampicin / Generic mfg.
Journal: Exploring targets of cell wall protein synthesis and overexpression mediated drug resistance for the discovery of potential M. tb inhibitors. (Pubmed Central) - Feb 8, 2022
The early detection of mycobacterium tuberculosis can be permanently cured by DOTS comprising Pyrazinamide (Z), Isoniazid (H), Rifampin (R) and Ethambutol (E)...Overexpression of these genes may produce drug-resistant due to dose misuse or the intake of quality compromised anti tubercular drug regimen. Therefore, in the present review there has been a necessity to report the second line antitubercular chemotherapeutics to target various proteins which are the building block of M. tb cell wall, overexpression of which may produce drug resistance.
- |||||||||| Trial completion date, Trial primary completion date, Combination therapy: SUDOCU: PanACEA Sutezolid Dose-finding and Combination Evaluation (clinicaltrials.gov) - Feb 8, 2022
P2b, N=75, Recruiting,
Therefore, in the present review there has been a necessity to report the second line antitubercular chemotherapeutics to target various proteins which are the building block of M. tb cell wall, overexpression of which may produce drug resistance. Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Nov 2021 --> Apr 2022
- |||||||||| Review, Journal: The pipeline of new molecules and regimens against drug-resistant tuberculosis. (Pubmed Central) - Nov 25, 2021
Compounds with novel targets involved in diverse bacterial functions such as cell wall synthesis (DrpE1, MmpL3), electron transport, DNA synthesis (GyrB), cholesterol metabolism and transcriptional regulation of ethionamide bioactivation pathways have advanced to early clinical studies with the potential to enhance antibacterial activity when added to new or established anti-TB drug regimens. Clinical validation of preclinical in vitro and animal model predictions of new anti-TB regimens may further improve the translational value of these models to identify optimal anti-TB therapies.
- |||||||||| Sivextro (tedizolid) / Merck (MSD), Nabriva Therap, delpazolid (LCB01-0371) / LegoChem Biosci, Sutezolid (PNU-100480) / Sequella
Preclinical, Journal: In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China. (Pubmed Central) - Nov 22, 2021
According to the multiple sequence alignment, novel 23srRNA mutations (A2267C and A2266G) in M. intracellulare and rplD mutations (Thr147Ala) in M. avium were identified in this study which have plausible involvement in rendering resistance against linezolid. This study showed that sutezolid harbors the strongest inhibitory activity against M. intracellulare, M. avium and M. kansasii in vitro, which provided important insights on the potential clinical application of oxazolidinones for treating SGM infections.
- |||||||||| Review, Journal: Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects. (Pubmed Central) - Sep 19, 2021
Finally, the most employed analytical techniques for oxazolidinone determination in different matrices, such as biological fluids, tissues, drugs and natural waters, are reviewed. Most are based on HPLC (High Performance Liquid Chromatography) coupled with UV-Vis or mass spectrometer detectors, but, to a lesser extent are also based on spectrofluorimetry or voltammetry.
- |||||||||| Lamprene (clofazimine) / Novartis
Review, Journal: An overview of new antitubercular drugs, drug candidates, and their targets. (Pubmed Central) - Jul 9, 2021
The last 10 years have made sudden progress giving some new and highly promising drugs including bedaquiline, delamanid, and pretomanid...These targets are either involved in cell wall biosynthesis, protein synthesis, DNA/RNA synthesis, or metabolism. This review discusses recent progress in the discovery of newly developed and Food and Drug Administration approved drugs as well as repurposed drugs, their targets, mode of action, drug-target interactions, and their structure-activity relationship.
- |||||||||| Sivextro (tedizolid) / Merck (MSD), Sutezolid (PNU-100480) / Sequella
PK/PD data, Journal: Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates. (Pubmed Central) - Jun 22, 2021
Once allometrically scaled to humans with a fixed exponent of 0.75 for apparent clearance and 1 for apparent volume of distribution, the AUCs of tedizolid and sutezolid were predicted reasonably well, whereas C was under-predicted for sutezolid. Both NHP and humanized concentration-time profiles will now be used in in vitro hollow-fiber pharmacodynamic experiments to determine if differences in drug exposures result in differences in Mycobacterium tuberculosis kill and emergence of resistance.
- |||||||||| Enrollment open, Combination therapy: SUDOCU: PanACEA Sutezolid Dose-finding and Combination Evaluation (clinicaltrials.gov) - May 9, 2021
P2b, N=75, Recruiting,
As well as identifying new compounds, we have identified the currently licensed antimicrobial doxycycline as showing efficacy against M . Not yet recruiting --> Recruiting
- |||||||||| Trial completion date, Trial primary completion date, Combination therapy: SUDOCU: PanACEA Sutezolid Dose-finding and Combination Evaluation (clinicaltrials.gov) - Nov 25, 2020
P2b, N=75, Not yet recruiting,
In a 4-week repeated dose toxicology study in rats, 19c appeared to have less bone marrow suppression than linezolid, which has been a major liability of the oxazolidinone class. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Nov 2021
- |||||||||| Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: SUDOCU: PanACEA Sutezolid Dose-finding and Combination Evaluation (clinicaltrials.gov) - Oct 16, 2019
P2b, N=75, Not yet recruiting,
Further evaluation could prove SZD superior to CLR in this combination. Trial completion date: Feb 2020 --> Dec 2020 | Initiation date: Aug 2019 --> Jun 2020 | Trial primary completion date: Jan 2020 --> Dec 2020
- |||||||||| Lamprene (clofazimine) / Novartis
Journal: An optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone Macozinone (PBTZ169). (Pubmed Central) - Oct 11, 2019
The efficacy of the standardized four-drug regimen (comprising isoniazid, rifampin, pyrazinamide, and ethambutol) for the treatment of tuberculosis (TB) is menaced by the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis Intensive efforts have been made to develop new antibiotics or to repurpose old drugs, and several of these are currently being evaluated in clinical trials for their antitubercular activity...At the MIC of each drug, MCZ with either bedaquiline (BDQ), clofazimine (CLO), delamanid (DMD), or sutezolid (STZ) reduced the bacterial burden by 2 logs compared to that achieved with the drugs alone, indicating synergism...For all the other drugs tested in combination with MCZ, no synergistic activity was observed. Neither antagonism nor increased cytotoxicity were found for most combinations, suggesting that MCZ could be added to different TB regimens without any significant adverse effects.
|
